Den Europæiske Union - dansk - EMA (European Medicines Agency)

astrazeneca ab - formoterol fumarate dihydrate, glycopyrronium bromide, budesonide - pulmonal sygdom, kronisk obstruktiv - medicin for obstruktiv sygdomme, - trixeo aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

astrazeneca ab - budesonide, formoterol fumarate dihydrate, glycopyrronium bromide - pulmonal sygdom, kronisk obstruktiv - medicin for obstruktiv sygdomme, - riltrava aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2 agonist or combination of a long-acting beta2 agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a. - beclometasone dipropionate, formoterol fumarate dihydrat, glycopyrronium bromid - pulmonal sygdom, kronisk obstruktiv - medicin for obstruktiv sygdomme, - maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year. copdmaintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or a combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5. asthmamaintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - glycopyrroniumbromid, neostigminmethylsulfat - injektionsvæske, opløsning - 0,5 + 2,5 mg/ml

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

2care4 aps - glycopyrroniumbromid - injektionsvæske, opløsning - 0,2 mg/ml

Den Europæiske Union - dansk - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a. - formoterol fumarate dihydrate, glycopyrronium, beclometasone dipropionate - pulmonal sygdom, kronisk obstruktiv - medicin for obstruktiv sygdomme, - vedligeholdelsesbehandling hos voksne patienter med moderat til svær kronisk obstruktiv lungesygdom (kol), der ikke er tilstrækkeligt behandlet ved en kombination af et inhaleret binyrebarkhormon og en langtidsvirkende beta2-agonist (for effekter på symptomer kontrol og forebyggelse af eksacerbationer se afsnit 5.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

merz pharmaceuticals gmbh - clostridium botulinum, type a toxin - pulver til injektionsvæske, opløsning - 100 enheder

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

merz pharmaceuticals gmbh - clostridium botulinum, type a toxin - pulver til injektionsvæske, opløsning - 200 enheder

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

merz pharmaceuticals gmbh - clostridium botulinum, type a toxin - pulver til injektionsvæske, opløsning - 50 enheder

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

kalceks as - hydromorphonhydrochlorid - injektions-/infusionsvæske, opløsning - 50 mg/ml